The QualityStocks Daily Newsletter for Wednesday August 26th, 2009 Blog  |  Video  |  Market Basics  |  Quotes & News  |  Clients  |  Partners  |  About Us  |  Contact Us

Today's Top 3 Investment Newsletters


Stock Egg.com (WAVE)


Wall Street E-News (DRGV)


Hot OTC.com (ATNO)

The QualityStocks Daily

Copper Mountain Mining Corporation (CUM.TO)

Lebed.biz, Topgun Stockpicks reported on Copper Mountain Mining Corporation (CUM.TO) yesterday, Streetwise Reports did earlier this month, and we highlight the Company as "One to Watch", here at the QualityStocks Daily Newsletter.

Trading on the Toronto Stock Exchange, Copper Mountain Mining Corporation is a Canadian resource company that is developing the Copper Mountain Project located 15 kilometers south of the town of Princeton in southern British Columbia. The Company currently owns 100 percent of the 18,000-acre Copper Mountain Project. Copper Mountain Mining Corporation has their corporate headquarters in Vancouver, British Columbia.

The Company's goal is to develop the Copper Mountain Project as a mid tier copper and precious metal mine. They are working to develop it to produce approximately 100 million pounds of copper per year by mid 2011. The Copper Mountain Project is a past producer of 1.7 billion pounds of Copper that closed in 1996. Consequently, there is significant developed infrastructure on site for the Company to build on.

The Copper Mountain Project acreage consists of prospective mining land held under a combination of 135-crown grants, 132 mineral claims, 14 mining licenses, eight cell mineral claims, and 12 fee simple lots. Initial exploration at Copper Mountain dates back to 1884. The Company completed one of B.C.'s largest drill exploration programs in 2007 and 2008 by drilling approximately 106,000 meters. The Company was successful in identifying a potential Super Pit and current drilling continues to concentrate on the areas between Pit 1, Pit 2, and Pit 3.  Additional drilling is planned to evaluate the surrounding areas and test the mineralization at depth.

Last Thursday, Copper Mountain Mining Corporation reported that Mitsubishi Materials Corporation closed the purchase whereby Mitsubishi acquired a 25 percent interest in the Copper Mountain Project located near Princeton, British Columbia. The Project is an open pit porphyry copper mine. The current resource is estimated at 5 billion pounds of copper at a 0.15 percent Cu cut-off. The resource estimate incorporates data from over 4,400 historical drill holes totaling approximately 400,000 meters, and 370 new drill holes, totaling 107,000 meters from the Company's 2007 and 2008 exploration programs.

We're tracking Copper Mountain Mining Corporation (CUM.TO) on our radar screens as "One to Watch", here at the QualityStocks Daily Newsletter.

Copper Mountain Mining Corporation (CUM.TO) closed today's session at $1.46 down $0.04 or 2.67 percent. Volume was 324,525 for a 3-month average of 166,611.

Raptor Pharmaceuticals Corp. (RPTP)

Today we are highlighting Raptor Pharmaceuticals Corp. (RPTP), as "One to Watch", here at the QualityStocks Daily Newsletter.

Raptor Pharmaceuticals Corp. is a development-stage biotechnology company with their corporate headquarters in Novato, California. They engage in the acquisition, development, and commercialization of pharmaceutical products in the United States. As an OTCBB-traded enterprise, they dedicate their efforts to speeding the delivery of new treatment options to patients. They do this by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise.

The company focuses on underserved patient populations. Their DR Cysteamine is an investigational, delayed-release (DR) oral formulation of cysteamine bitartrate. This is for the potential treatment of nephropathic cystinosis (cystinosis), which is a rare lysosomal storage disease. Raptor’s DR Cysteamine formulation may require less frequent dosing and reduce gastrointestinal side effects. They are also developing DR Cysteamine for the potential treatment of Non-alcoholic Steatohepatitis (NASH), Huntington’s Disease, and Batten Disease. Raptor is also in clinical development of Convivia™. They are developing Convivia™ for the potential treatment of aldehyde dehydrogenase (ALDH2) deficiency.

Raptor Pharmaceuticals Corp. bases their preclinical programs on bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins. The design of these is to target cancer, neurodegenerative disorders, and infectious diseases. Their preclinical programs include HepTide™, WntTide™ and NeuroTrans™.

Earlier this year, Raptor Pharmaceuticals announced the completion of patient enrollment in their Phase 2a open-label clinical trial to evaluate cysteamine bitartrate (cysteamine) in patients diagnosed with non-alcoholic steatohepatitis (NASH). NASH patients currently can only manage their disease through weight control, diet, and exercise. NASH is a progressive form of liver disease and is one of the leading causes of cirrhosis in the U.S. It accounts for approximately 10 percent of newly diagnosed cases of chronic liver disease.

On July 28, 2009, Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. announced that they have entered into a definitive merger agreement. The merger will result in a NASDAQ-listed biopharmaceutical company. It will have a pipeline of mid- to late-stage clinical development candidates and preclinical drug targeting platforms designed to improve drug delivery of existing therapeutics for orphan indications and underserved patient populations. It is anticipated that the merged company will go by the name Raptor Pharmaceuticals Corp.

Yesterday, Raptor Pharmaceuticals Corp. announced that they raised an aggregate $5 million of gross proceeds. This is through a private placement of units and through the exercise of warrants originally issued in connection with their May/June 2008 private placement. This August 2009 Private Placement resulted in gross proceeds to the Company of approximately $2.4 million, or $2.3 million after placement agent fees and other expenses. The Warrant Exchange raised approximately $2.6 million in net proceeds for Raptor.

We're tracking Raptor Pharmaceuticals Corp. (RPTP) on our radar screens as "One to Watch", here at the QualityStocks Daily Newsletter.

Today, Raptor Pharmaceuticals Corp. (RPTP) closed at $0.40 up $0.03 or 8.11 percent. Volume was 1,528,110 for a 3-month average volume of 156,303.

TorreyPines Therapeutics, Inc. (TPTX)

Today we are highlighting TorreyPines Therapeutics, Inc. (TPTX) as "One to Watch", here at the QualityStocks Daily Newsletter.

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company. Trading on the NASDAQ Global Market, the company's commitment is to providing patients with better alternatives to existing therapies. This is via the research, development, and commercialization of small molecule compounds. TorreyPines Therapeutics, Inc. has their corporate headquarters in La Jolla, California. They are part of the Diagnostic Substances industry in the Healthcare sector.

The company's goal is to develop versatile product candidates, each capable of treating a number of acute and chronic diseases and disorders. These include acute migraine and other forms of acute and chronic pain. They are developing two ionotropic glutamate receptor antagonists. Their lead product candidate, tezampanel, has successfully completed three Phase I clinical trials, five Phase IIa proof of concept trials in multiple pain models, and one Phase IIb clinical trial in acute migraine in which tezampanel met the primary endpoint of headache pain response at two hours post-dose. 

Last December, TorreyPines announced that oral administration of NGX426 demonstrated a statistically significant reduction in spontaneous pain, hyperalgesia, and allodynia. This is compared to placebo following intradermal injections of capsaicin in a human experimental model of cutaneous pain, hyperalgesia, and allodynia. NGX426 is a prodrug of tezampanel.

TorreyPines Therapeutics, Inc. pursues in-licensing and corporate partnerships to expand and advance their product candidate portfolio. They also pursue these to fund their discovery programs. In April 2003, the Company acquired worldwide rights and all intellectual property for product candidates NGX424 and NGX426 from Eli Lilly & Co. In November 2008, they sold their Alzheimer’s disease genetics research program to Eisai Co., Ltd. for an upfront cash payment. In November 2008, they licensed to QR Pharma, Inc. the worldwide rights to Posiphen™, bisnorcymcerine and phenserine. The company is currently evaluating partnership opportunities for tezampanel and NGX426 as treatments for acute and chronic pain.

TorreyPines Therapeutics, Inc. and Raptor Pharmaceuticals Corp. recently entered into a definitive merger agreement. The merger will result in a NASDAQ-listed biopharmaceutical company which will have a pipeline of mid- to late-stage clinical development candidates and preclinical drug targeting platforms designed to improve drug delivery of existing therapeutics for orphan indications and underserved patient populations. It is anticipated that the merged company will go by the name Raptor Pharmaceuticals Corp.

We're keeping and eye on TorreyPines Therapeutics, Inc. (TPTX), and we have them locked on our radar screens as "One to Watch", here at the QualityStocks Daily Newsletter.

TorreyPines Therapeutics, Inc. (TPTX) closed Wednesday's trading session at $0.53 up $0.3505 or 195.26 percent. Volume was 13,216,770 for a 3-month average volume of 305,968.

HST Global Inc. (HSTC)

Last week, OTCReporter.com reported on HST Global Inc. (HSTC), Willy Wizard, Stock Stars, HotOTC.com, Stock Rich, Penny Invest, Stock Egg, Cool Penny Stocks did earlier this month, and we highlight the Company, here at the QualityStocks Daily Newsletter.

HST Global Inc. is an Integrated Biotechnology Health and Wellness company that is developing and/or acquiring a network of Wellness Centers worldwide. These centers are primarily focused on the immunotherapy and alternative treatment of late stage cancer. Trading on the OTCBB, the Company has their headquarters in Hampton, Virginia. They began operations in 2007.

In addition, HST Global Inc. intends to acquire innovative products for the treatment of late stage cancer. The Company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.

Earlier this year, HST Global, Inc. announced an initiative EBITDA Capital, LLC has started on behalf of HST Global, Inc. This is for the placement of health and wellness center operations within the Native American Community. HST Global, Inc. has requested that EBITDA Capital initiate negotiations with known contacts within the Native American community for placing health and wellness centers on tribal reservations.

In July, HST Global, Inc. announced the launch of a cognitive function product endorsed and recommended by Dr. Kyl Smith under a Joint Venture with Dalham, LLC (an affiliate company of The Health Network, Inc.). The new product will be named Focus-Up®. This product is a powdered dietary supplement energy drink.

Last week, HST Global, Inc. announced the official launch of the FocusUP® Website located at www.focusup.com. Ron Howell, CEO/President stated, "We are pleased to announce the launch of our new FocusUP® website. With the introduction of the new website, we will have the ability to educate the public on the benefits of FocusUP ®, Dr. Kyl Smith's cognitive function product. We encourage you to go to www.focusup.com to learn more."

HST Global Inc. (HSTC) closed Wednesday's session at $0.49 for no change on volume of 305,880. The 3-month average is 1,355 shares.

Dyax Corp. (DYAX)

Street Insider, Investorsunderground.com, Today's Financial News, OTC Picks, and Stock Stars reported recently on Dyax Corp. (DYAX), and we highlight the Company, here at the QualityStocks Daily Newsletter.

Trading on the NASDAQ Global Market, Dyax focuses on advancing novel biotherapeutics for unmet medical needs. Headquartered in Cambridge, Massachusetts, their emphasis is on oncology and inflammatory indications. The Company utilizes their proprietary drug discovery technology to identify antibody, small protein, and peptide compounds for clinical development. Dyax Corp. issued an initial public offering (IPO) in August 2000.

Biotechnology entrepreneur Henry E. Blair co-founded Dyax Corp. in 1995. Dyax Corp. came about from the merger between Biotage, a separations instrument chromatography firm, and Protein Engineering Corporation, from which they acquired their patented proprietary phage display technology. This technology rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax sold their non-core business, Biotage, in 2003. This was so they could focus exclusively on biotherapeutics.

Dyax's lead product candidate is DX-88 (ecallantide). This is a recombinant small protein currently undergoing evaluation for its therapeutic potential in two separate indications. On June 1, 2009, Dyax submitted a response to the FDA's Complete Response letter regarding the review of Dyax's Biologics License Application (BLA) of DX-88 for the treatment of hereditary angioedema (HAE). The FDA accepted the submission and assigned the Company's BLA a new Prescription Drug User Fee Act (PDUFA) action date of December 1, 2009. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S., for this indication.  

DX-88 is also undergoing evaluation for the prevention of blood loss during on-pump cardiothoracic surgery (CTS). This is through their partner, Cubist Pharmaceuticals. Dyax licensed, to Cubist Pharmaceuticals, the intravenous formulation of DX-88 for surgical indications in North America and Europe. DX-88 and other compounds in Dyax’s pipeline were identified using their patented phage display technology. Dyax leverages this technology broadly with more than 70 revenue generating licenses and collaborations for therapeutic discovery. They also leverage this technology in non-core areas such as affinity separations, diagnostic imaging, and research reagents.

Today, Dyax Corp. announced successful advancement into Phase 1 clinical trials of two candidates identified using their proprietary phage display technology by licensees of the Company's Licensing and Funded Research Program (LFRP). The Company's proprietary drug discovery platform, phage display, provides an efficient means to identify compounds that interact with a wide array of therapeutic targets. Their antibody phage display libraries allows for the rapid isolation of fully human target-specific antibodies from a library of billions of unique antibodies.

Dyax Corp. (DYAX) closed Wednesday's session at $3.58 down $0.01 or 0.28 percent. Volume was 282,584 for a 3-month average of 425,875


Today, we choose to highlight NEXT Inc. (NXTI), here at the QualityStocks Daily Newsletter.

Trading on the OTCBB, NEXT Inc. is a sales and marketing organization that has their corporate headquarters in Chattanooga, Tennessee. They design, develop, produce, market, and distribute licensed and branded promotional products and imprinted sportswear. Their brands are American Biker, Campus Traditions, American Wildlife USA, and RPM Sports USA. The Company markets to leading corporations, colleges, and universities in North America.

The Company is one of the major companies in the licensed promotional products and imprinted sportswear industries. NEXT Inc. has expanded their distribution to include e-commerce. This is where they market a significant portion of their most popular licensed products. NEXT Inc.'s imprinted sportswear includes headwear, polo shirts, long-sleeve shirts, fleece wear, and sweat pants.

NEXT Inc.'s American Biker is a leading producer in biker clothing. Their product offerings include men's biker shirts, women's biker shirts, biker apparel, and accessories. NEXT Inc., through their RPM Sports USA is also an officially licensed distributor of automotive apparel.

Their Campus Traditions USA is a top source for officially licensed college apparel. These include products such as Texas shirts, USC sweatshirts, Duke t-shirts, and more, that represent the 100 plus schools that they sell. The Campus Traditions USA brand offers embroidered college sweatshirts, college t-shirts, and other college clothing. They offer unique designs on a variety of body styles. These also include long sleeve t-shirts, ringer tees, textured drop needle polo, crew sweatshirts, and hooded sweatshirts.

The Company also has their American Wildlife clothing. This brand offers American Wildlife shirts, wildlife sweatshirts, wildlife t-shirts, and several other American Wildlife branded clothing. Their commitment is to high quality garments and print. Overall, NEXT Inc.'s customers include national, large regional, and specialty retail chains. In addition, they sell to corporate accounts, college bookstores, motor sports, souvenir and gift shops, and golf shops.

NEXT Inc. (NXTI) closed today's session at $0.0180 up $0.0060 or 50.00 percent. Volume was 1,000 shares for a 3-month average of 7,975.

Medical Connections Holdings, Inc. (MCTH)

Pennypic, SmallCap Voice, Titan Stocks, Stock Guru, and OTC Picks reported earlier on Medical Connections Holdings, Inc. (MCTH), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Headquartered in Boca Raton, Florida, Medical Connections Holdings, Inc. is a national provider of medical recruitment and staffing services. The Company came into being in 2002 to satisfy the increasing need for highly qualified healthcare professionals. Their business is to identify, select, and place the industry’s most talented healthcare specialists, nurses, pharmacists, physicians, and hospital management executives. Medical Connections provides recruiting and staffing services for permanent and contract positions, leaving options for both clients and candidates to decide the optimal formula for working together.

Medical Connections corporate commitment is to deliver recruiting and staffing solutions that maximizes the value of the human assets in any healthcare enterprise. They work to deliver fast, cost effective, and high quality services that allow their clients to access and profit from the best medical professionals in the United States and internationally.

The Company works so that searching and retaining the most qualified medical and scientific personnel is not time consuming and costly for their customers. They utilize the extensive expertise of their Recruiters and Pronto Advisers™. They make the searching and retaining process fast, easy, comprehensive, and cost effective for those who use their services. Medical Connections selects, recruits, screens, and places talented medical professionals, domestically and abroad. This is to meet the growing needs facing the health care industry.

Last week, Medical Connections Holdings, Inc. announced they were named to Staffing Industry Analysts’ list of fastest-growing U.S. staffing firms for 2009.

“We’re just thrilled to be recognized in one of the most prestigious reports in our industry,” said Joseph Azzata, CEO of Medical Connections. “And what’s more, our incredible growth and leading position within the staffing community have been all the more reinforced during one of the slowest economic periods in history.”

Medical Connections Holdings, Inc. (MCTH) closed today's trading at $0.49 up $0.03 or 6.52 percent. Volume was 19,114 for a 3-month average of 19,469.

Anavex Life Sciences Corp. (AVXL)

Today we choose to highlight Anavex Life Sciences Corp. (AVXL), here at the QualityStocks Daily Newsletter.

Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drug targets for the treatment of cancer, inflammatory, and neurological diseases such as Alzheimer's, epilepsy and depression. Headquartered in Geneva, Switzerland, the Company has their proprietary SIGMACEPTOR™ Discovery Platform. It involves the designing of drug compounds that fulfill specific criteria based on new scientific advances and marketplace needs.
The Company's SIGMACEPTOR™-N program involves the development of drug candidates that target Alzheimer's disease, epilepsy, depression, pain and the like. Anavex Life Sciences' lead drug candidates exhibit high, non-exclusive affinity for sigma receptors. These drug candidates show strong evidence for anti-amnesic, neuroprotective, anti-apoptotic, anti-oxidative, anti-inflammatory, anti-convulsive, anti-depressant, and anxiolytic properties.

Anavex's SIGMACEPTOR™-C program involves the development of drug candidates targeting cancer. The Company's lead drug candidates for this also exhibit high, non-exclusive affinity for sigma receptors. These show strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties. These drug candidates are for cancers such as colon, prostate, breast, and lung.

The Company's ANAVEX 7-1037 has shown the ability to delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies. In addition, the Company has several series of sigma ligands currently at different stages of development. These target cancer, acute ischemic stroke, multiple sclerosis, and Parkinson's disease.

The Company expects that their lead drug candidate ANAVEX 2-73– targeting Alzheimer's disease will enter first clinical trials this year. Anavex Life Sciences Corp. has completed pre-clinical testing on ANAVEX 2-73 (Alzheimer’s disease) and is currently preparing the Investigational New Drug file to advance the compound to human clinical trials. Anavex has more than 30 novel drug candidates waiting in the wings as well.

Today, Anavex Life Sciences Corp. (AVXL) closed at $2.49 down $0.01 or 0.40 percent. Volume was 6,273 for a 3-month average of 10,651.

The QualityStocks Company Corner

Solanex Management (SLNX)
DataCall Technologies (DCLT)
Superlattice Power Inc. (SLAT)

Superlattice Power (SLAT) BLOG
Helix Wind Corp. (HLWX) BLOG
ImmuneRegen Bio (IRBS) BLOG
Dana Resources (DANR) BLOG

Solanex Management, Inc. (SLNX)

The QualityStocks Daily Newsletter would like to spotlight Solanex Management, Inc. (SLNX) Today, Solanex Management, Inc. closed trading at $0.30, which was up $0.06 or 25.00 percent. Their volume today was 324,676 shares.

The Boards of Solanex Management Inc. and Geo Finance Corporation jointly announced today that they have signed a Memorandum of Understanding (”MOU”) to form a Joint Venture. According to the terms of the MOU, Solanex will provide working capital to the Joint Venture and Geo Finance will provide its business models and full inclusion of its client lists, in addition to all sales and marketing IT of Geo Exchange renewable energy programs.

Solanex Management, Inc. (SLNX) is focused on developing, manufacturing and selling the Thermal Destructor; developing, manufacturing and selling the portable Steam Injection System; and investing in other viable business opportunities, including mineral resource properties. Through a joint venture agreement with ecoTECH, the company has secured a relationship critical to achieving success.

The company’s Thermal Destructor is a self contained, soil residue combustion system designed to clean contaminated sites by sterilizing soil. The system consists of a high efficiency, waste or gas-fired combustion chamber and a next-generation exhaust gas, low-pressure drop liquid scrubber effective in trapping pollutants in air emissions. A common use of the Thermal Destructor is cleaning up hydrocarbon spills at the end of the life of a production well.

The Steam Injection System has been designed specifically for use in oil fields where high-pressure steam can be injected into the oil formation to help dilute and separate heavy oil from the earth. Solanex Management believes the most immediate market for the system is to companies who are in the bitumen/heavy oil exploitation business where oil can’t be produced unless it is heated or diluted. Unlike current steam generation systems, the Steam Injection System is portable, costs less to manufacture, and can utilize various fuel sources to create steam.

Going forward, the company is working on identifying companies to partner with to better expose its technology to the intended markets. Solanex Management is also analyzing and searching for synergistic business opportunities that will allow the company to utilize its existing technology in other business applications. With marketing and manufacturing plans in place, Solanex Management is positioned to capitalize on its revolutionary technologies. Disclaimer

DataCall Technologies, Inc. (DCLT)

The QualityStocks Daily Newsletter would like to spotlight DataCall Technologies, Inc. (DCLT). Today, DataCall Technologies, Inc. closed trading at $0.03, for no change. Their volume today was 33,833 shares. Their 3-month average volume is 77,551 shares.

QualityStocks today announced that their audio interview with Data Call Technologies, Inc. (DCLT) and Chairman Jim Ammons is now available. The complete interview can be heard at: www.qualitystocks.net/videocharts.php?chartvid_id=335

DataCall Technologies, Inc. (DCLT) announced today that they have finalized agreements and development initiatives to provide global meteorological conditions, Doppler radar images, and weather forecasts. Continuing their corporate strategy, the Company has already begun marketing these products to entities outside the U.S.

DataCall Technologies, Inc. (DCLT) was founded with the vision to develop and deliver the first wirelessly fed information feed containing sports scores and sports news. As the company enhanced their product, they began offering additional content sources such as financial news, national and world news, weather, traffic, horoscope, trivia and more. During this time of development and growth, digital signage began gaining recognition as an explosive and lucrative industry.

Over the past few years, DataCall has shown impressive growth in its customer base and gross revenues. By establishing early strategies and corporate partnerships, the company has been able to penetrate nearly all digital signage venues. DataCall’s feeds are now delivered to a broad range of locales including: medical centers, banks, hotels, resorts, schools, gas stations, universities, restaurants, bill boards, and Public Broadcast Stations.

It has been forecasted that North American digital signage spending will total $1.6 billion in 2009 (up 24% from 2008) and will continue to grow to a projected $2.6 billion by 2011. The increasing affordability of displays and other essential equipment, ability to update feeds in real-time, and the capability to send targeted messages during various times of the day continue to fuel the growth of this quickly emerging industry.

Data Call is committed to expanding its product offerings and plans to move into other vertical markets within its targeted industry. Moving forward, Data Call will be focusing on growing its subscriber base, while maintaining aggressive expenditure management. The company is also in negotiations to acquire a likeminded company, which will enable a stronger penetration in the digital signage and IT networks technology industries. Disclaimer

DataCall Technologies, Inc. Blog

DataCall Technologies, Inc. News:

QualityStocks Features Data Call Technologies, Inc. in Exclusive Interview

Data Call Technologies Now Offers Comprehensive Weather Coverage to 215 Countries

Data Call Technologies Announces Q2 2009 Financial Results - 44% Increase in Revenues

Superlattice Power Inc. (SLAT)

The QualityStocks Daily Newsletter would like to spotlight Superlattice Power Inc. (SLAT). Today, Superlattice Power, Inc. closed trading at $0.67, which was up $0.02 or 3.08 percent. Their volume today was 26,550 shares. Their 3-month average volume is 231,045 shares.

Superlattice Power, Inc. is focused on using its resources and efforts to develop and market lithium-powered vehicles and products for use in residential and commercial properties. Using its technology, the company is able to covert scooters, bicycles, mopeds, motorcycles, cars and even homes and businesses into zero-emission, lithium-powered vehicles and facilities.

The company has made considerable progress in advancing its next generation lithium-powered batteries. It is currently developing a new cathode material that can be integrated into a Lithium-ion polymer battery to substantially increase operating voltage range as well as energy density. With the new cathode material, electric vehicles will be able to travel over 200 miles versus the current 120-140 range.

Superlattice Power, Inc. recently announced that its new cathode material can now enter large-scale production. This technological breakthrough will give Superlattice Power the ability to produce all the necessary physical materials at a batch of 100kg each, making it more practical and affordable for the public to switch from gasoline-powered vehicles to emissions-free vehicles powered by Supperlattice's unique technology.

As prices for fossil fuel energy continue to rise, consumers and businesses are seeking an alternative way to power their world. Scientists, analysts and automotive executives have agreed that rising fuel costs and environmental concerns will cause the sales of hybrid and electric vehicles to skyrocket, and Superlattice has positioned itself to take advantage of the anticipated demand. Disclaimer

Superlattice Power, Inc. Daily Blog

Superlattice Power Inc. News:

OTC Select Announces Daily Stock Watch

Superlattice Power, Inc. and Global Giant in Asia Submit Letter of Support to Department of Energy USA for Mass Scale Production, Job Creation, Training and Development of Safe, High Energy Density, Cost Effective, Electric Vehicle Battery Packs

Superlattice Power Inc. Has a Commitment to Partner with Large Asian Lithium-Ion Battery Manufacturer

eDOORWAYS Corporation (EDWY)

The QualityStocks Daily Newsletter would like to spotlight eDOORWAYS Corporation (EDWY) Today, eDOORWAYS Corp. closed trading at $0.0220, which was down $0.0005 or 2.22 percent. Their volume today was 2,428,787 shares. Their 3-month average volume is 115,095 shares.

eDOORWAYS Corp. (EDWY) explained its service platform business revenue model in anticipation of its October 1, 2009, soft launch in Austin, Texas.

eDOORWAYS Corp. is committed to solving lifestyle problems for consumers while driving traffic to suppliers and service providers who offer innovative merchandise and solutions. The company has the potential to completely change the future landscape of business by offering a unique and comprehensive service that saves consumers valuable time and money. By uniting a consumer with the larger global consumer community, retailers, and manufacturers in an effective new way, eDOORWAYS promotes “dynamic” commerce, as opposed to the static model currently in existence.

The Company plans to capitalize on several emerging new trends. These newly created opportunities include: the large success of Web 2.0 Internet community service offerings such as MySpace, the movement towards niche marketing and targeted advertising, the introduction of new technologies that enable instantaneous, online presentation of information, and the rising consumer preference for using the Internet to gain information before making purchasing decisions.

eDOORWAYS plans to introduce local services using a city-by-city strategy that will minimize capital requirements, reduce staffing requirements, and optimize generated revenues. Ten major cities are targeted for launch in the first year. Advertising, PR campaigns and viral word-of-mouth will be used to give a public presentation to experts as well as educate the market.

The key benefits offered to consumers include a higher level of engagement with vendors, trusted information from other consumers, and superior customer service. Revenues will be generated through advertising placement fees, premium services, preferential placement fees, and a percentage of sales transactions. eDOORWAYS' progressive vision and professional management team makes it an attractive investment opportunity. Disclaimer


Superlattice Power, Inc. (SLAT) Moves Forward With Manufacturing Plans

Superlattice Power, Inc., emerging leader in the development of the next generation of batteries for electric and hybrid vehicles, is continuing with their recently announced plans to establish a manufacturing unit for their advanced lithium ion polymer batteries. The company is working with an unnamed Asian company to set up the first pilot scale production unit in Mooresville, North Carolina. The plant is expected to have an initial production capacity of 36,000 cells per year, enough to supply 450 electric vehicles. Once fully operational, the plant is targeted to produce approximately 100,000 cells annually.

The advantage of Superlattice’s advanced battery is the use of a cathode material that has a superlattice molecular structure, giving the battery a significant new potential for increased energy. Superlattice has developed a cathode material for lithium ion batteries with a capacity of nearly 1.5 times currently available cathode materials. The new battery is being developed to allow an electric car to go up to 200 miles on a single charge, while still being lightweight, smaller, safer, and less expensive than conventional designs. The company has also developed a unique and proprietary chemical process for the industrial scale production of the high-purity nano cathode materials required for the battery.

In general, cathode materials are the most expensive part of lithium-ion batteries. Cathode materials can have different crystalline structures, including a series of superlattice structures. The superlattice structure allows more lithium to be stored, resulting in a higher energy density. The materials used by Superlattice have been carefully selected to ensure that they are safe, environmentally friendly, and more affordable. The fact that the company is also developing the technologies needed to produce the new cathode materials at industrial levels is critical to the future of the battery.

Superlattice Power Inc. is also working with EV Innovations Inc. (EVII) on the battery pack design, and has a contractual agreement with the company to supply the lithium ion batteries for their electric vehicles.

Helix Wind Corp. (HLXW) Inks Deal to Offer Financing of Small Wind Turbines

Helix Wind Corp. is a global renewable energy firm. The company is engaged in the design, manufacturing and sale of small wind vertical axis turbines designed to generate 300W, 1kW, 2.0kW, 4.0kW, and 50kW of clean, renewable electricity.

Helix Wind recently announced that it has established a joint venture with Atoll Financial Group to develop products and financing mechanisms for individuals, small businesses and commercial users. The company’s distributors will also be offered short-term and trade finance to help in the distribution of Helix Wind’s small wind turbines.

The benefit for individuals and small businesses is a smaller cash outlay and the ability to match expenditure with their electric bill savings. For commercial users, the financing will create cash flow. Importantly, Helix Wind distributors will be able to purchase and carry inventory. This will greatly minimize turnaround time for customers and help the company’s distributors manage cash flows.
The arrangement with Atoll Financial will also enable Helix Wind to build manufacturing facilities, if needed, in those markets where demand supports the investment as well as finance export sales into countries where Helix Wind does not have a local partner.

Helix Wind CEO Ian Gardner said, “We are excited to be the only small wind company to offer individuals and small businesses financing for small wind turbines, which can make purchasing renewable energy much more accessible to consumers.” Mr. Gardner also added “ This joint venture with Atoll Financial Group provides Helix Wind with the operational flexibility we need to grow.”

IR BioSciences Holdings, Inc. (IRBS) Subsidiary Explores Possibility of Partnership with Archimedes Development Ltd.

ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced this morning that it has executed a Material Transfer Agreement (MTA) with Archimedes Development Limited. This collaboration enables the companies to identify possible synergies between their technology platforms.

“Multiple studies in different model systems have shown that Homspera can protect experimental animals and enhance their immune responses to vaccine-delivered antigens, DNA-encoded viral proteins or tumor antigens, as well as provide protection in our anthrax and influenza therapeutic studies,” stated Hal Siegel, Ph.D., ImmuneRegen’s Vice President and Chief Scientific Officer.

He continued, “In addition to these findings in animals where Homspera has been administered intranasally as a liquid, inhaled or injected under the skin, we have shown in laboratory studies that Homspera can stimulate blood-forming stem cells to produce more white blood cell precursors, particularly those for granulocytes and macrophages, mature blood cells which play a significant role in immune responses. The ability to administer Homspera intranasally is one we are particularly interested in pursuing. Mucosal vaccination may be more efficacious than injected vaccines for diseases like influenza, intestinal diseases and HIV/AIDS. At times, such as pandemic influenza treatment or vaccination, intranasal administration might be desirable.”

Alan Smith, Ph.D., Archimedes’ Vice President of Research & Development, commented, “We recognize the growing need to improve the efficacy of available antigens and to facilitate mass vaccination by means of innovative approaches such as mucosal administration. As a recognized leader in this field we are excited to be collaborating with ImmuneRegen to apply our world-leading expertise and technology platforms to the intranasal delivery of Homspera.”

Dana Resources (DANR) Plans Major Production Program for Collota Gold Deposit

Dana Resources is a precious and base metals exploration company that has been gaining momentum of late. While things have been looking up for the young company, Dana Resources took a major step towards enhancing their financial future when they announced the initiation of the production program at its Collota gold deposit in Northern Peru. Currently, Dana Resources owns and operates seven mining projects which are located in Peru’s most prolific mining regions.

The company has a plan in place to produce gold for sale by 2012 under the proposed model which will permit all zones to commence shortly. As for an estimated time frame, the permitting process is expected to run 12 to 18 months with a production setup time which is estimated at 18 to 24 months.

By comparison, IRLS MINERA, a neighboring company, successfully put its deposit into production under the same model after raising $20 million. While successful, the IRLS MINERA deposit is 40 percent smaller than Dana Resources’ Collota deposit.

Dana Resources plans on processing the oxide zone first due to the low cost open pit heap leach process. Initially, Dana Resources expects to net $15 per ton of ore. The Collota gold deposit oxide zone has 27 million tons available to be processed using a cut-off grade of 0.25 grams per ton. At this cut-off, Dana Resources will net over $400 million profit from the oxide zone. The sulphide zone has over 13 million tons ready to be processed with expectations to net approximately $150 million profit.

When asked what this process will mean to the aggressive young company, their Board of Directors stated, “We are very excited to initiate our production program at Collota. As previously stated, our plan is to simultaneously increase the size and grade of the Collota deposit and continue permitting the project for production. We believe with further drilling, the Collota deposit could reach upwards of 3 million ounces of gold.”

Peru holds around 16 percent of the world’s known mineral resources and has some of the richest mineral reserves in the world and is one of the highest producing countries of precious and base metals in Latin America which may allow this production program to exceed all expectations.

Currently, Dana Resources in trading over the counter in the $0.39 range. With this innovative news and a strong business model in place, Dana Resources may be an up-and-coming company to keep an eye on.


Sponsors of the Day

The QualityStocks Public Company Sponsor News



About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

Home | Blog | Video | Market Basics | Media | Partners | Clients | About Us | Contact Us | Disclaimer | Unsubscribe
Copyright 2006-2009 QualityStocks 3370 N. Hayden Rd. Suite 123-591 Scottsdale, AZ 85251 480-374-1336